Skip to main content
MedPathMedPath Home
Clinical Trials/NCT05764629
NCT05764629
Active, not recruiting
Not Applicable

An Observational Study of Risk Factors Influencing Glycemic Status and Optimized Treatment on Post-chronic Pancreatitis Diabetes Mellitus

Changhai Hospital1 site in 1 country324 target enrollmentSeptember 1, 2021
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsChronic PancreatitisDiabetes Mellitus
Drugspharmacologic approaches to glycemic treatment

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Pancreatitis
Sponsor
Changhai Hospital
Enrollment
324
Locations
1
Primary Endpoint
Hemoglobin A1c (HbA1c)
Status
Active, not recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

To explore the risk factors influencing glycemic status, optimized treatment, and prognosis of post-chronic pancreatitis diabetes mellitus (PPDM-C).

Detailed Description

The present study was an observational study aimed to explore risk factors influencing glycemic status, optimized treatment, and prognosis of post-chronic pancreatitis diabetes mellitus. The observation items included clinical characteristics, blood glucose control and incidence of complications of PPDM-C.

Registry
clinicaltrials.gov
Start Date
September 1, 2021
End Date
December 31, 2030
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Zhuan Liao

Principal Investigator

Changhai Hospital

Eligibility Criteria

Inclusion Criteria

  • •patients with diagnosis of chronic pancreatitis and diabetes mellitus.
  • •participants with painless chronic pancreatitis were diagnosed with diabetes within 2 years of the diagnosis of chronic pancreatitis.
  • •participants with painful chronic pancreatitis were diagnosed with diabetes after the first attack of chronic pancreatitis.

Exclusion Criteria

  • •participants with suspected malignant tumors of the pancreas or other sites of body, or participants in the terminal stage of severe disease
  • •serious mental illness, lesion of liver or kidney, pregnancy, breast-feeding or planning pregnancy
  • •definitely diagnosed type 1 diabetes, type 2 diabetes, or other metabolic diseases that affect blood glucose
  • •autoimmune pancreatitis
  • •Scarcity of information related to HbA1c
  • •death or loss of follow-up during follow-up

Outcomes

Primary Outcomes

Hemoglobin A1c (HbA1c)

Time Frame: through study completion, an average of 1 year

measure the control of blood glucose of every 3 months

Secondary Outcomes

  • Adverse events(through study completion, an average of 1 year)

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Hyperglycemia and Acute PancreatitisAcute Pancreatitis (AP)Diabetes Mellitus
NCT06590233Shanghai Changzheng Hospital4,500
Not yet recruiting
Not Applicable
Clinical Study on Exploring High Risk Factors Inducing the Progress of DiabetesT2D
NCT05980754Peking University Third Hospital90
Recruiting
Not Applicable
Analysis of Relevant Influencing Factors of Glycemic Control in Patients With DiabetesGlycemic Control
NCT05854862Nanjing First Hospital, Nanjing Medical University10,000
Completed
Not Applicable
The Risk Factors and Its Prognosis of Hyperglycemia Secondary to Pancreatic SurgeryPancreatic SurgeyDiabetes Mellitus
NCT06585046Shanghai Changzheng Hospital382
Not yet recruiting
Not Applicable
Diabetes Self-management With Continuous Glucose MonitoringType 1 Diabetes
NCT06453434Nordsjaellands Hospital500